Humacyte, Inc. (NASDAQ:HUMA - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $5.48, but opened at $5.91. Humacyte shares last traded at $5.92, with a volume of 550,174 shares.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price objective on shares of Humacyte in a research note on Monday, April 1st. Piper Sandler restated a "neutral" rating and issued a $4.00 target price on shares of Humacyte in a research note on Tuesday, March 26th. Finally, Benchmark restated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Monday.
Read Our Latest Research Report on HUMA
Humacyte Stock Performance
The company has a market capitalization of $764.49 million, a price-to-earnings ratio of -6.55 and a beta of 1.27. The company has a debt-to-equity ratio of 1.20, a current ratio of 4.52 and a quick ratio of 4.52. The stock has a 50 day moving average price of $3.52 and a two-hundred day moving average price of $3.16.
Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. During the same period last year, the business earned ($0.21) earnings per share. On average, analysts predict that Humacyte, Inc. will post -0.9 EPS for the current fiscal year.
Hedge Funds Weigh In On Humacyte
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company's stock valued at $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Humacyte during the 1st quarter valued at about $972,000. Private Advisor Group LLC lifted its holdings in shares of Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company's stock valued at $988,000 after purchasing an additional 222,144 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Humacyte by 139.5% during the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company's stock valued at $1,043,000 after purchasing an additional 207,333 shares in the last quarter. Finally, Rokos Capital Management LLP lifted its holdings in shares of Humacyte by 122.5% during the 3rd quarter. Rokos Capital Management LLP now owns 200,000 shares of the company's stock valued at $587,000 after purchasing an additional 110,097 shares in the last quarter. Institutional investors own 44.71% of the company's stock.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
